Strides acquires Sandoz branded generics portfolio to expand Sub-Saharan Africa footprint

Strides Pharma has agreed to acquire a portfolio of branded generic products from Sandoz across Sub-Saharan Africa, covering anti-infective, cardiovascular, and dermatology segments. The $12 million deal spans four key markets and includes both full acquisition and continued marketing rights, positioning Strides among the region's top five pharmaceutical companies.

Strides Pharma Science's subsidiary Strides Pharma International AG has entered into definitive agreements with Sandoz to acquire and in-license a portfolio of branded generic products across Sub-Saharan Africa, according to an official announcement. The transaction covers four key markets - Western Sahara (encompassing 10 countries), Ghana, Nigeria, and Kenya, and includes multiple brands across anti-infective, cardiovascular, and dermatology therapeutic segments, several with annual sales exceeding $1 million each.

Strides Pharma Science is an Indian pharmaceutical company with operations across emerging markets, specialising in branded generics. Sandoz, a Novartis division, is a global leader in generic and biosimilar medicines. The portfolio includes products being fully acquired by Strides and select products that Strides will continue to market on behalf of Sandoz under a manufacturing and supply agreement. The initial consideration is $12 million, payable at closing and funded through internal accruals. The transaction is expected to close by the end of the second quarter of fiscal year 2027, subject to regulatory and antitrust approvals. This development matters for the African pharmaceutical market, where branded generics represent a significant segment given physician prescribing patterns and patient trust in established brands.

The acquisition positions Strides among the top five pharmaceutical companies in Sub-Saharan Africa by sales and among the top two players in the representable market. For the healthcare industry, the deal reflects continued consolidation in emerging market pharmaceutical distribution, where scale enables broader prescriber access and supply chain efficiencies. Stakeholders including healthcare providers, pharmacies, and patients across the affected markets will experience portfolio expansion from the combined product offerings. The transaction is expected to be EPS-accretive for Strides, supported by profitable branded sales and synergy realisation from strengthened commercial platforms.